A Genetically Engineered Biomimetic Nanodecoy for the Treatment of Liver Fibrosis.

Liver fibrosis, arising from factors such as viral infections or metabolic disorders, represents an ongoing global health challenge and is a major risk factor for hepatocellular carcinoma. Unfortunately, there are no clinically approved drugs available for its treatment. Recent studies have illuminated the pivotal role of macrophage recruitment in the pathogenesis of liver fibrosis, presenting a potential therapeutic target. Therefore, it holds great promise to develop novel anti-fibrotic therapies capable of inhibiting this process. Herein, a drug-loaded biomimetic nanodecoy (CNV-C) is developed by harnessing genetically engineered cellular vesicles for the treatment of liver fibrosis. CNV-C is equipped with a C-C motif chemokine receptor 2 (CCR2)-overexpressed surface, enabling it to selectively neutralize elevated levels of C-C motif chemokine ligand 2 (CCL2), thereby reducing macrophage infiltration and the subsequent production of the fibrogenic cytokine transforming growth factor β (TGF-β). Moreover, curcumin, an anti-fibrotic agent, is loaded into CNV-C and delivered to the liver, facilitating its efficacy in suppressing the activation of hepatic stellate cells by blocking the downstream TGF-β/Smad signaling. This combinational therapy ultimately culminates in the alleviation of liver fibrosis in a mouse model induced by carbon tetrachloride. Collectively, the findings provide groundbreaking proof-of-concept for employing genetically modified nanodecoys to manage liver fibrosis, which may usher in a new era of anti-fibrotic treatments.